FDA lifts partial clinical hold on Curis's TakeAim Lymphoma study of emavusertib

CURIS INC

FDA lifted partial clinical hold on TakeAim Lymphoma Phase 1/2 study; enrollment to resume Q3 2022.
Partial hold on TakeAim Leukemia study remains under FDA Division of Hematologic Malignancies 1.
Hold lifted after FDA agreement on rhabdomyolysis management and enrollment of ≥9 patients at 200 mg emavusertib plus ibrutinib.
Preliminary clinical data update from TakeAim Lymphoma expected in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.